You are here

Ipsen

Ipsen beefs up in oncology, buying US biopharma Epizyme

Pharmaforum

Mon, 06/27/22 - 10:52 am

First-quarter biotech risers work hard for the win

EP Vantage

Thu, 04/21/22 - 10:32 am

Lantheus Medical

Ipsen plans sale of consumer health business for €350m

Pharmaforum

Fri, 02/11/22 - 11:40 am

consumer health

Mayoly Spindler

Ipsen withdraws NDA for rare bone disease treatment less than 3 months after winning priority review

Endpoints

Sat, 08/14/21 - 01:47 pm

Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases

Pharmaforum

Mon, 08/2/21 - 10:54 am

neurodegenerative disease

Ipsen bets up to $363M on another shot at a debilitating condition related to Parkinson's disease

Endpoints

Thu, 07/15/21 - 11:50 pm

levodopa-induced dyskinesia

ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen

Fierce Pharma

Thu, 05/20/21 - 12:15 pm

clinical trials

Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO

Fierce Pharma

Wed, 05/12/21 - 11:39 pm

FDA Approvals Roundup: Qwo, Tremfya, Dysport

RAPS.org

Wed, 07/15/20 - 11:19 pm

Endo International

Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 project

Fierce Pharma

Fri, 05/29/20 - 12:27 pm

Ipsen scraps pivotal trial as partial clinical hold drags on

Fierce Biotech

Thu, 03/26/20 - 10:40 am

clinical trials

osteochondromas

Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts

Fierce Pharma

Fri, 02/28/20 - 11:50 pm

Spark Therapeutics

Ipsen takes €669M hit as palovarotene's prospects wither

Fierce Biotech

Thu, 02/13/20 - 10:47 am

Top Companies in Pharm Country Ranked by Revenue

BioSpace

Fri, 02/7/20 - 11:46 pm

Bristol-Myers Squibb

Ovid Therapeutics

Ipsen’s quick fix backfires

EP Vantage

Fri, 01/24/20 - 10:48 am

Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns

Bloomberg

Fri, 12/6/19 - 09:50 am

fibrodysplasia ossificans progressiva

osteochondromas

Ipsen doubles down on rare bone disease

EP Vantage

Wed, 10/16/19 - 07:18 pm

Blueprint Medicines

Clementia Pharmaceuticals

FDA approves Ipsen’s Dysport to treat upper limb spasticity in children

Pharmaceutical Business Review

Fri, 09/27/19 - 09:43 am

upper limb spasticity

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Pharmaceutical Business Review

Mon, 07/8/19 - 10:25 am

liposomal irinotecan

pancreatic cancer

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Endpoints

Mon, 02/25/19 - 10:04 am

Clementia Pharmaceuticals

Pages